WAVEMAN · COMPANY

ABVC · Abvc Biopharma, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

ABVC

Name: ABVC BIOPHARMA, INC. (ABVC) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ABVC BIOPHARMA, INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001173313

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

0.0%

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

10 funds added or opened last quarter

below 82% of Pharma & Biotech

REVENUE

+0.0% year over year

below 56% of Pharma & Biotech

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

1.7% of shares outstanding short · 5.6 days to cover · settled 2026-07-31

below 68% of Pharma & Biotech

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 10 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for ABVC BIOPHARMA, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

VANGUARD CAPITAL MANAGEMENT LLC

374,499.0 sh

$591.7K

GEODE CAPITAL MANAGEMENT, LLC

228,042.0 sh

$360.4K

VANGUARD FIDUCIARY TRUST CO

97,363.0 sh

$153.8K

STATE STREET CORP

72,800.0 sh

$115.0K

CITADEL ADVISORS LLC

72,091.0 sh

$113.9K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Extended Market Index Fund

$138.8K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$184.9K POSITION · AS OF 2026-03-31

0.0%

Fidelity Series Total Market Index Fund

$35.5K POSITION · AS OF 2026-02-28

0.0%

Fidelity Nasdaq Composite Index Fund

$8.0K POSITION · AS OF 2026-02-28

0.0%

Fidelity Total Market Index Fund

$40.7K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$296.0K	$296.0K	$152.4K	$969.8K
GROSS PROFIT	—	$508.8K	$-149.6K	$683.4K
OPERATING INCOME	$-7.2M	$-4.7M	$-6.8M	$-15.1M
NET INCOME	$-7.9M	$-4.9M	$-7.8M	$-16.4M
EPS (DILUTED)	-0.39	-0.42	-1.80	-5.19
OPERATING CASH FLOW	$-3.0M	$-1.8M	$-4.2M	$-7.4M
CASH	$681.5K	$248.4K	$60.2K	$85.3K

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE